Tag: OCEAN trial
-
Stopping DOACs After Successful AF Ablation: OCEAN Trial Feasible in Low-Risk Patients
Overview: Rethinking Anticoagulation After AF Ablation New data from the OCEAN trial suggest that stopping direct oral anticoagulants (DOACs) after a successful atrial fibrillation (AF) ablation may be feasible for low-risk patients. This challenges the long-standing practice of continuing anticoagulation based solely on prior AF history and CHADS2‑VASc scoring, and invites clinicians to re-evaluate individual…
-
Stopping DOACs After AF Ablation: OCEAN Trial Findings
New Evidence Suggests DOACs May Be Stopped After Successful AF Ablation in Low-Risk Patients A new analysis from the OCEAN trial presents a provocative finding for clinicians and patients managing atrial fibrillation (AF): for low-risk individuals who have undergone successful AF ablation, continuing oral anticoagulants (DOACs) may not offer a clear advantage in preventing stroke…
-
Stopping DOACs After Successful AF Ablation: Feasible in Low-Risk Patients? Insights from OCEAN Trial
New Evidence Questions Long-Term Anticoagulation After AF Ablation For patients with atrial fibrillation (AF) who undergo successful ablation, clinicians often face the question: should a patient continue taking a direct oral anticoagulant (DOAC) or switch to an antiplatelet strategy like aspirin? The OCEAN trial, presented in New Orleans, Louisiana, provides new data suggesting that, among…